INDOCO REMEDIES Latest Share Price (INDOCO)
TODAY IN ONE LINE
INDOCO fell 2.5% on light volume, lagging Nifty's -0.5% move.
With a market cap of ₹2,076.83 Cr., it trades at a P/E of 368.85. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
INDOCO REMEDIES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 58.9% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest INDOCO REMEDIES News
What changed recently?
Recent events, corporate actions, and announcements.
INDOCO REMEDIES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for INDOCO REMEDIES, framed against the sector median so the premium or discount is obvious at a glance.
INDOCO REMEDIES trades at a P/E of 368.85× and P/B of 2.21×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
INDOCO REMEDIES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INDOCO REMEDIES — derived from the latest tape, not yesterday's close.
INDOCO REMEDIES last traded at ₹225.6 with an intraday range of ₹224–₹231.2 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹225.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 244.27 | +18.67 | +8.27% |
| R3 | 237.07 | +11.47 | +5.08% |
| R2 | 234.13 | +8.53 | +3.78% |
| R1 | 229.87 | +4.27 | +1.89% |
| PIVOT | 226.93 | 1.33 | 0.59% |
| CURRENT | 225.60 | — | — |
| S1 | 222.67 | -2.93 | -1.30% |
| S2 | 219.73 | -5.87 | -2.60% |
| S3 | 215.47 | -10.13 | -4.49% |
| S4 | 208.27 | -17.33 | -7.68% |
INDOCO is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹225.5–₹229.6
Trading Below opening range, showing Bearishness
INDOCO REMEDIES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for INDOCO REMEDIES — consolidated or standalone — with margins, YoY growth and key ratios inline.
INDOCO REMEDIES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,076.83 Cr. and reported EPS of ₹7.04.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 1,845 | 1,845 ▲ 0.0% |
| Sales Growth YoY %Derived | 10.84% | 10.84% |
| Other Income | 3 | 3 ▲ 0.0% |
| Total Income | 1,849 | 1,849 ▲ 0.0% |
| 542 | 542 ▲ 0.0% | |
| Gross ProfitDerived | 1,304 | 1,304 ▲ 0.0% |
| Gross Margin %Derived | 70.64% | 70.64% |
| 1,162 | 1,162 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 142 | 142 ▲ 0.0% |
| OPM %Derived | 7.68% | 7.68% |
| 246 | 246 ▲ 0.0% | |
| Profit Before Tax (PBT) | -107 | -107 ▲ 0.0% |
| -8 | -8 ▲ 0.0% | |
| Effective Tax %Derived | 7.33% | 7.33% |
| Total Profit for Period | -99 | -99 ▲ 0.0% |
| Less: Non-controlling Interests | -4 | -4 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | -95 | -95 ▲ 0.0% |
| Net Profit Margin %Derived | -5.16% | -5.16% |
| PAT Growth YoY %Derived | -29.03% | -29.03% |
| Earnings Per Share (EPS ₹) | -10.31 | -10.31 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 13 | 13 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 1,955 | 1,955 ▲ 0.0% |
| Material Cost % of RevenueDerived | 23.06% | 23.06% |
| Employee Cost % of RevenueDerived | 23.07% | 23.07% |
| Other Cost % of RevenueDerived | 39.89% | 39.89% |
| Interest Coverage (x)Derived | 0.13x | 0.13x |
| Period | Mar 2020 | Jun 2020 | Mar 2021 | May 2021 | Mar 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,107 | 1,107 ▲ 0.0% | 1,242 ▲ 12.2% | 1,242 ▲ 0.0% | 1,541 ▲ 24.1% | 1,541 ▲ 0.0% | 1,669 ▲ 8.3% | 1,669 ▲ 0.0% | 1,817 ▲ 8.9% | 1,817 ▲ 0.0% | 1,665 ▼ 8.4% | 1,665 ▲ 0.0% | 1,845 ▲ 10.8% | 1,845 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 12.19% | — | 24.10% | 24.10% | 8.30% | 8.30% | 8.91% | 8.91% | -8.38% | -8.38% | 10.84% | 10.84% | |
| Other Income | 2 | 2 ▲ 0.0% | 3 ▲ 27.9% | 3 ▲ 0.0% | 2 ▼ 25.3% | 2 ▲ 0.0% | 2 ▲ 0.4% | 2 ▲ 0.0% | 10 ▲ 320.9% | 10 ▲ 0.0% | 5 ▼ 44.7% | 5 ▲ 0.0% | 3 ▼ 38.9% | 3 ▲ 0.0% | |
| Total Income | 1,109 | 1,109 ▲ 0.0% | 1,245 ▲ 12.2% | 1,245 ▲ 0.0% | 1,543 ▲ 24.0% | 1,543 ▲ 0.0% | 1,671 ▲ 8.3% | 1,671 ▲ 0.0% | 1,827 ▲ 9.3% | 1,827 ▲ 0.0% | 1,670 ▼ 8.6% | 1,670 ▲ 0.0% | 1,849 ▲ 10.7% | 1,849 ▲ 0.0% | |
330 | 330 ▲ 0.0% | 354 ▲ 7.2% | 354 ▲ 0.0% | 457 ▲ 29.0% | 457 ▲ 0.0% | 521 ▲ 14.1% | 521 ▲ 0.0% | 559 ▲ 7.3% | 559 ▲ 0.0% | 498 ▼ 10.9% | 498 ▲ 0.0% | 542 ▲ 8.7% | 542 ▲ 0.0% | ||
| Gross ProfitDerived | 776 | 776 ▲ 0.0% | 887 ▲ 14.3% | 887 ▲ 0.0% | 1,084 ▲ 22.1% | 1,084 ▲ 0.0% | 1,147 ▲ 5.8% | 1,147 ▲ 0.0% | 1,258 ▲ 9.7% | 1,258 ▲ 0.0% | 1,167 ▼ 7.3% | 1,167 ▲ 0.0% | 1,304 ▲ 11.7% | 1,304 ▲ 0.0% | |
| Gross Margin %Derived | 70.14% | 70.14% | 71.48% | 71.48% | 70.35% | 70.35% | 68.76% | 68.76% | 69.23% | 69.23% | 70.08% | 70.08% | 70.64% | 70.64% | |
653 | 653 ▲ 0.0% | 663 ▲ 1.6% | 663 ▲ 0.0% | 757 ▲ 14.1% | 757 ▲ 0.0% | 861 ▲ 13.8% | 861 ▲ 0.0% | 1,014 ▲ 17.7% | 1,014 ▲ 0.0% | 1,067 ▲ 5.3% | 1,067 ▲ 0.0% | 1,162 ▲ 8.8% | 1,162 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 123 | 123 ▲ 0.0% | 224 ▲ 82.0% | 224 ▲ 0.0% | 327 ▲ 46.0% | 327 ▲ 0.0% | 286 ▼ 12.6% | 286 ▲ 0.0% | 244 ▼ 14.6% | 244 ▲ 0.0% | 99 ▼ 59.4% | 99 ▲ 0.0% | 142 ▲ 42.9% | 142 ▲ 0.0% | |
| OPM %Derived | 11.13% | 11.13% | 18.06% | 18.06% | 21.25% | 21.25% | 17.15% | 17.15% | 13.44% | 13.44% | 5.96% | 5.96% | 7.68% | 7.68% | |
97 | 97 ▲ 0.0% | 95 ▼ 1.7% | 95 ▲ 0.0% | 93 ▼ 2.4% | 93 ▲ 0.0% | 96 ▲ 2.7% | 96 ▲ 0.0% | 141 ▲ 47.9% | 141 ▲ 0.0% | 181 ▲ 28.0% | 181 ▲ 0.0% | 246 ▲ 35.7% | 246 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 29 | 29 ▲ 0.0% | 132 ▲ 361.9% | 132 ▲ 0.0% | 237 ▲ 79.2% | 237 ▲ 0.0% | 193 ▼ 18.5% | 193 ▲ 0.0% | 136 ▼ 29.6% | 136 ▲ 0.0% | -74 ▼ 154.8% | -74 ▲ 0.0% | -107 ▼ 43.2% | -107 ▲ 0.0% | |
4 | 4 ▲ 0.0% | 39 ▲ 773.3% | 39 ▲ 0.0% | 82 ▲ 109.9% | 82 ▲ 0.0% | 51 ▼ 38.2% | 51 ▲ 0.0% | 39 ▼ 23.3% | 39 ▲ 0.0% | 4 ▼ 90.8% | 4 ▲ 0.0% | -8 ▼ 318.2% | -8 ▲ 0.0% | ||
| Effective Tax %Derived | 15.61% | 15.61% | 29.51% | 29.51% | 34.56% | 34.56% | 26.22% | 26.22% | 28.56% | 28.56% | -4.81% | -4.81% | 7.33% | 7.33% | |
| Total Profit for Period | 24 | 24 ▲ 0.0% | 93 ▲ 285.8% | 93 ▲ 0.0% | 155 ▲ 66.4% | 155 ▲ 0.0% | 142 ▼ 8.1% | 142 ▲ 0.0% | 97 ▼ 31.8% | 97 ▲ 0.0% | -78 ▼ 180.4% | -78 ▲ 0.0% | -99 ▼ 26.6% | -99 ▲ 0.0% | |
| Less: Non-controlling Interests | — | — | — | — | — | — | — | — | -1 | -1 ▲ 0.0% | -4 ▼ 188.4% | -4 ▲ 0.0% | -4 ▲ 15.7% | -4 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 24 | 24 ▲ 0.0% | 93 ▲ 285.8% | 93 ▲ 0.0% | 155 ▲ 66.4% | 155 ▲ 0.0% | 142 ▼ 8.1% | 142 ▲ 0.0% | 98 ▼ 30.8% | 98 ▲ 0.0% | -74 ▼ 174.9% | -74 ▲ 0.0% | -95 ▼ 29.0% | -95 ▲ 0.0% | |
| Net Profit Margin %Derived | 2.18% | 2.18% | 7.49% | 7.49% | 10.05% | 10.05% | 8.53% | 8.53% | 5.42% | 5.42% | -4.43% | -4.43% | -5.16% | -5.16% | |
| PAT Growth YoY %Derived | — | — | 285.78% | — | 66.36% | 66.36% | -8.11% | -8.11% | -30.78% | -30.78% | -174.89% | -174.89% | -29.03% | -29.03% | |
| Earnings Per Share (EPS ₹) | 2.62 | 2.62 ▲ 0.0% | 10.10 ▲ 285.5% | 10.10 ▲ 0.0% | 16.80 ▲ 66.3% | 16.80 ▲ 0.0% | 15.44 ▼ 8.1% | 15.44 ▲ 0.0% | 10.68 ▼ 30.8% | 10.68 ▲ 0.0% | -7.99 ▼ 174.8% | -7.99 ▲ 0.0% | -10.31 ▼ 29.0% | -10.31 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.0% | 9 ▲ 0.1% | 9 ▲ 0.0% | 9 ▲ 0.1% | 9 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -2 | -2 ▲ 0.0% | -1 ▲ 53.0% | -1 ▲ 0.0% | -5 ▼ 519.8% | -5 ▲ 0.0% | 1 ▲ 127.0% | 1 ▲ 0.0% | 0 ▼ 81.3% | 0 ▲ 0.0% | -4 ▼ 1629.6% | -4 ▲ 0.0% | 13 ▲ 405.6% | 13 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 1,080 | 1,080 ▲ 0.0% | 1,113 ▲ 3.0% | 1,113 ▲ 0.0% | 1,307 ▲ 17.4% | 1,307 ▲ 0.0% | 1,478 ▲ 13.1% | 1,478 ▲ 0.0% | 1,691 ▲ 14.4% | 1,691 ▲ 0.0% | 1,745 ▲ 3.2% | 1,745 ▲ 0.0% | 1,955 ▲ 12.1% | 1,955 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 23.74% | 23.74% | 24.42% | 24.42% | 25.55% | 25.55% | 24.69% | 24.69% | 26.69% | 26.69% | 23.80% | 23.80% | 23.06% | 23.06% | |
| Employee Cost % of RevenueDerived | 23.18% | 23.18% | 22.07% | 22.07% | 19.06% | 19.06% | 19.33% | 19.33% | 19.92% | 19.92% | 23.67% | 23.67% | 23.07% | 23.07% | |
| Other Cost % of RevenueDerived | 35.83% | 35.83% | 31.34% | 31.34% | 30.05% | 30.05% | 32.28% | 32.28% | 35.87% | 35.87% | 40.45% | 40.45% | 39.89% | 39.89% | |
| Interest Coverage (x)Derived | 2.00x | 2.00x | 6.79x | 6.79x | 17.57x | 17.57x | 8.61x | 8.61x | 4.01x | 4.01x | -0.22x | -0.22x | 0.13x | 0.13x |
INDOCO REMEDIES segment analysis : revenue and profit mix.
Disclosed business segments at INDOCO REMEDIES with their share of revenue and profit, switchable between consolidated and standalone reporting.
INDOCO REMEDIES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for INDOCO REMEDIES.
Our AI distills the core fundamental drivers supporting INDOCO REMEDIES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
INDOCO REMEDIES's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 58.86% signals insider confidence and long-term commitment.
TTM revenue growth of 21.90% demonstrates robust recent sales momentum despite profitability challenges.
Positive operating cash flow of ₹157.78 Cr latest quarter supports operational liquidity.
Diversified pharmaceutical portfolio across 12+ therapeutic areas reduces concentration risk.
5-year revenue CAGR of 11.45% shows consistent top-line expansion trajectory.
Key Risks.
ROE of -0.51% reflects severe shareholder value destruction and poor capital deployment.
Net profit margin of -5.31% TTM indicates ongoing unprofitability despite revenue growth.
Latest quarterly EPS of -₹1.00 FY25 versus ₹3.82 FY23 signals earnings collapse.
Operating margin compressed to 0.86% FY26 from 14.97% FY24 signals structural cost challenges.
Minimal dividend yield of 0.08% offers negligible income to shareholders despite payout.
Flip Conditions.
Valuation risk. a P/E above 480 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.14. Balance sheet risk re-prices growth multiples fast.
Income thesis breaks if the dividend is cut or yield falls below 0.04%.
INDOCO REMEDIES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INDOCO REMEDIES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
INDOCO REMEDIES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for INDOCO REMEDIES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
INDOCO REMEDIES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for INDOCO REMEDIES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in INDOCO REMEDIES stood at 53.3% of traded volume, against a 20-day average of 41.1%.
INDOCO REMEDIES announcements: results, concalls, ratings, M&A.
Filings INDOCO REMEDIES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
INDOCO REMEDIES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 111 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Indoco Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
General Updates
Indoco Remedies Limited has informed the Exchange about intimation to shareholders holding shares in physical mode regarding mandatory furnishing of…
Acquisition
Indoco Remedies Limited has informed the Exchange about the incorporation of Wholly Owned subsidiary of the Company in the name and style of…
Trading Window
Indoco Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
General Updates
Indoco Remedies Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)…
Investor decks & rating reports.
INDOCO REMEDIES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue INDOCO REMEDIES has declared, sequenced by announce and record date.
INDOCO REMEDIES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
INDOCO REMEDIES insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in INDOCO REMEDIES as reported to SEBI — buying and selling signals from the people who know the business best.
INDOCO REMEDIES insider activity below tracks 14 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Shanteri Investment Pvt Ltd | Insider | 19 Mar 2025 | buy | +12.2 K | ₹27.9 L | ₹229.59 |
| Shanteri Investment Pvt Ltd | Insider | 18 Mar 2025 | buy | +26.0 K | ₹56.87 L | ₹218.74 |
| Shanteri Investment Pvt Ltd | Insider | 11 Mar 2025 | buy | +2.6 K | ₹5.78 L | ₹222.23 |
| Shanteri Investment Pvt Ltd | Insider | 10 Mar 2025 | buy | +19.3 K | ₹44.59 L | ₹231.04 |
| Shanteri Investment Pvt Ltd | Insider | 07 Mar 2025 | buy | +8.2 K | ₹19.16 L | ₹235.00 |
| Shanteri Investment Pvt Ltd | Insider | 05 Mar 2025 | buy | +9.4 K | ₹21.21 L | ₹224.49 |
| Shanteri Investment Pvt Ltd | Insider | 04 Mar 2025 | buy | +9.4 K | ₹21.13 L | ₹224.79 |
| MADHURA SURESH KARE | Insider | 14 Feb 2025 | buy | +10.0 K | ₹24.93 L | ₹249.25 |
| MADHURA SURESH KARE | Insider | 11 Feb 2025 | buy | +9.5 K | ₹24.69 L | ₹259.85 |
| Sundeep V Bambolkar | Insider | 28 Jan 2025 | buy | +4.0 K | ₹10.04 L | ₹251.02 |
About INDOCO REMEDIES: business, sector, key facts.
What INDOCO REMEDIES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
INDOCO REMEDIES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: INDOCO, BSE: 532612.
Indoco Remedies Limited is a diversified pharmaceutical company headquartered in Mumbai, India, with a history dating back to 1945. Its core business is the manufacture, marketing, and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs) both domestically in India and internationally. Their product portfolio spans a wide range of therapeutic areas, catering to diverse health needs.
The company's pharmaceutical offerings encompass a broad spectrum of therapeutic categories. These include products for stomatological (dental), gastrointestinal, respiratory, and anti-infective treatments. They also manufacture vitamins, minerals, and nutrients; ophthalmological and dermatological products; urological, anti-diabetic, and gynaecological medications; lifestyle management aids; pain and analgesic treatments; and cardiac medications. Their branded generics include analgesic tablets and topical preparations, anti-hypertensives, protein supplements, multivitamins, antibiotics, oral rehydration solutions, antacids, antihistamines, anti-haemorrhoidal creams, and calcium preparations.
Beyond its pharmaceutical production, Indoco Remedies offers a substantial suite of analytical and contract research services. Their analytical services provide crucial support to the pharmaceutical industry, encompassing impurity profiling, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables testing, lyophilization studies, reference standard development, forced degradation studies, and chromatographic method development and validation. This signifies a commitment to quality control and research within the broader pharmaceutical sector.
Furthermore, Indoco extends its services into engineering and contract research. The company provides engineering services including architectural design, lighting, mechanical and utility engineering, project and construction management, electrical and control systems, piping, structural design, data transfer system design and process engineering. Their contract research capabilities encompass custom synthesis of molecules and intermediates, process chemistry research and development, non-infringing process design and scale-up, and analytical method development and validation solutions. This integrated approach allows Indoco to offer comprehensive solutions to clients, ranging from initial research and development to large-scale manufacturing and analytical testing.
In summary, Indoco Remedies Limited operates a multifaceted business model, combining pharmaceutical product development and manufacturing with comprehensive analytical and engineering services, along with contract research and manufacturing capabilities. This diversified approach allows them to participate across numerous stages of the pharmaceutical value chain, both domestically and internationally.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about INDOCO REMEDIES (INDOCO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of INDOCO REMEDIES (INDOCO)?
The current share price of INDOCO REMEDIES (INDOCO) is ₹225.60. Today, the stock has declined by ₹5.90 (2.55%), trading in a range of ₹224.00 to ₹231.20. The stock opened at ₹225.50 with a trading volume of 1,06,790 shares.
02Is INDOCO REMEDIES stock a good investment for long-term?
INDOCO REMEDIES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,076.83 Cr., P/E ratio of 368.85, ROE of -0.51%, and ROCE of 4.26%. The dividend yield stands at 0.09%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of INDOCO REMEDIES stock?
The 52-week high price of INDOCO REMEDIES (INDOCO) is ₹291.00, while the 52-week low is ₹162.19. Currently trading at ₹225.60, the stock is 39.1% above its 52-week low and 22.47% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy INDOCO REMEDIES stock at the current price?
Whether to buy INDOCO REMEDIES stock at ₹225.60 depends on multiple factors. The stock is currently trading with a P/E ratio of 368.85 and P/B ratio of 2.21. Today's performance shows a loss of 2.55%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of INDOCO REMEDIES and when is the next dividend?
INDOCO REMEDIES offers a dividend yield of 0.09%, which means for every ₹100 invested at the current price of ₹225.60, you can expect to receive approximately ₹0.09 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of INDOCO REMEDIES?
INDOCO REMEDIES's key financial metrics include: P/E Ratio: 368.85, P/B Ratio: 2.21, ROE: -0.51%, ROCE: 4.26%, Dividend Yield: 0.09%, EPS: ₹7.04, Book Value: ₹100.98, and Debt-to-Equity: 0.64. The company's market cap stands at ₹2,076.83 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is INDOCO REMEDIES stock performing today in the market?
INDOCO REMEDIES stock opened at ₹225.50 and is currently trading at ₹225.60, showing a decline of ₹5.90 (2.55%). The intraday high is ₹231.20 and low is ₹224.00. The trading volume stands at 1,06,790 shares, indicating moderate market participation today.
08What is the P/E ratio of INDOCO REMEDIES and what does it indicate?
INDOCO REMEDIES has a Price-to-Earnings (P/E) ratio of 368.85, which means investors are willing to pay 368.85 for every ₹1 of earnings. With an EPS of ₹7.04, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about INDOCO REMEDIES (INDOCO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.